Brand Ofev Vs Generic Nintedanib

—

—

Has Ofev Gone Generic?

Yes. The FDA has approved generic versions of Ofev (nintedanib) in both 100 mg and 150 mg capsules, giving patients with idiopathic pulmonary fibrosis a lower-cost alternative to the brand. Several manufacturers received approval for generic nintedanib in 2026. Cipla and Apotex introduced generic nintedanib capsules in early 2026, and Dexcel Pharma USA received FDA final approval for its nintedanib capsules, described by the company as the generic equivalent of Ofev, in mid-2026. The generic is being distributed through specialty pharmacies and established pharmaceutical distribution channels to support patient access across the US.

Is Generic Nintedanib the Same as Ofev?

Generic nintedanib contains the same active ingredient (nintedanib esylate) as brand-name Ofev and must meet the same FDA standards for strength, quality, purity, and stability. An FDA-approved generic is required to be therapeutically equivalent to the brand, meaning it is expected to work the same way in the body and provide the same clinical benefit. Nintedanib works by inhibiting several tyrosine kinases involved in the scarring process in the lungs, which helps slow the decline in lung function in idiopathic pulmonary fibrosis (IPF) and certain other progressive fibrosing lung diseases. Both brand and generic are taken as 150 mg capsules twice daily in most adults, with a 100 mg twice-daily option used in specific situations such as mild liver impairment or side-effect management, always under a prescriber’s direction.

Brand Ofev vs. Generic Nintedanib: Side by Side

The table below summarizes the main differences between brand Ofev and generic nintedanib. Both share the same active ingredient and FDA-required standards; the primary differences are manufacturer, availability, and cost.

Is There a Cheaper Alternative to Ofev?

The most direct lower-cost alternative to brand Ofev is generic nintedanib, which contains the same active ingredient and is now FDA-approved. For IPF specifically, the other FDA-approved antifibrotic medication is pirfenidone (brand name Esbriet), which also has generic versions available; however, nintedanib and pirfenidone are different drugs, and only your pulmonologist can determine which is appropriate for you. Beyond switching to a generic, most patients lower their real out-of-pocket cost through financial assistance rather than by changing drugs: manufacturer copay cards for commercially insured patients, patient assistance programs for the uninsured, and independent foundation grants for Medicare patients. If you need help affording nintedanib, QuickRx can review every assistance option you may qualify for.

How Much Does Nintedanib Cost?

Brand Ofev is a high-cost specialty medication, with an average retail price reported in the range of roughly $16,000 per month, though very few patients pay full price because of insurance and assistance programs. Discount-coupon pricing published by third-party sites has been reported significantly lower than average retail. Because FDA-approved generic nintedanib only became available in the US in 2026, established generic retail pricing is still stabilizing, and generic prices are generally expected to come in below the brand as more manufacturers enter the market and pharmacies list the product. What you actually pay depends on your insurance, your pharmacy, whether you receive the brand or a generic, and which assistance programs you qualify for. See the pricing disclaimer at the end of this article.

Does Medicare Pay for Ofev or Generic Nintedanib?

Medicare Part D plans generally cover nintedanib (brand Ofev and its generics), but your out-of-pocket cost depends on your plan’s formulary tier, deductible, and coverage phase. Because federal law prohibits using a manufacturer copay card with Medicare, Medicare patients who face high nintedanib costs typically pursue independent charitable foundation grants or patient assistance programs instead. Recent changes to Medicare Part D have also introduced an annual out-of-pocket cap for covered prescription drugs, which can meaningfully limit what some patients pay over a year; check your specific plan for current details. QuickRx patient navigators help Medicare patients identify and apply for every grant and program they may qualify for, at no cost.

How Can I Lower the Cost of Nintedanib?

Most patients lower their nintedanib cost through a combination of insurance coordination, manufacturer copay assistance, patient assistance programs, and independent foundation grants, rather than by paying retail. The right path depends on your insurance type:

• Commercially insured: You may qualify for a manufacturer copay card, and eligible patients can pay as little as $0 per month.
• Uninsured or underinsured: Patient assistance programs may provide nintedanib at no cost if you meet income requirements.
• Medicare or Medicaid: You cannot use a manufacturer copay card, but you may qualify for independent charitable foundation grants.
• Everyone: Choosing an FDA-approved generic, when clinically appropriate and available, may lower your cost.

QuickRx handles the screening and paperwork for all of these at no charge. Call (917) 830-2525 to find out what you would pay.

Need Help Affording Nintedanib?

917-830-2525

—

Frequently Asked Questions About Generic Nintedanib

Medical References & Sources

1. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Accessed July 2026.
2. Nintedanib. Lexidrug (formerly Lexi-Drugs), UpToDate / Wolters Kluwer Health. Accessed April 2026.
3. Richeldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071-2082.
4. Pulmonary Fibrosis Foundation. Treatment Options and Financial Assistance Resources. Accessed July 2026.
5. MedlinePlus (U.S. National Library of Medicine). Nintedanib Drug Information. Accessed July 2026.
6. Ofev (nintedanib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2025.

—

Pricing disclaimer: Cost figures in this article are approximate, are provided for general educational purposes only, and are not price quotes. Retail and discount pricing referenced reflects third-party published figures as of July 2026 and varies by pharmacy, location, insurance, and date. Generic nintedanib pricing in the US is still stabilizing following its 2026 launch. QuickRx does not guarantee any specific price or savings amount. Contact QuickRx or your pharmacy for a current, personalized cost estimate.

Written by: Paola Larrabure, Pharma Content Manager, QuickRx Specialty Pharmacy

Medically Reviewed by: Julia Kravtsova, PharmD, Head Patient Navigator, QuickRx Specialty Pharmacy

Last Updated: July 2026